Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Beam designed its automated CD34+ HSPC process for manufacturing of BEAM-101 to have the flexibility for a wide range of patient-starting material and variable cell numbers, while maintaining robust cell yield and high drug product quality suitable for use in the BEACON Phase 1/2 clinical trial. Today's data highlight the following: About Beam Therapeutics | --- | |---------------------| | | | Contacts: | | Investors: | | Holly Manning | | Beam Therapeutics | | hmanning@beamtx.com | | Media: | | Dan Budwick ...